PTH and parathyroid gland carcinoma: Calcimimetics are orally active agonists of the CaSR, used for treating PTH hypersecretion in end stage kidney disease and parathyroid carcinoma by enhancing receptor sensitivity to extracellular calcium and inhibiting PTH secretion.